Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Fagron NV

Healthcare US ARSUF

26.53USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

27.0027.00
LowHigh

52 Week Range

20.0327.00
LowHigh

Fundamentals

  • Previous Close 26.53
  • Market Cap1945.89M
  • Volume2500
  • P/E Ratio18.17
  • Dividend Yield1.51%
  • EBITDA167.13M
  • Revenue TTM952.17M
  • Revenue Per Share TTM13.03
  • Gross Profit TTM 432.00M
  • Diluted EPS TTM1.46

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 117.59M 104.30M 84.44M 87.77M 76.82M
Minority interest -0.50200M -0.44700M -0.49700M -0.45400M -0.37500M
Net income 91.02M 80.55M 70.55M 69.61M 61.00M
Selling general administrative - - - - -
Selling and marketing expenses - - - - -
Gross profit 432.00M 395.68M 332.61M 286.17M 247.50M
Reconciled depreciation 43.96M 36.35M 34.52M 31.30M 26.48M
Ebit - - - 92.41M 87.07M
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 147.45M 134.37M 112.71M 101.17M 89.92M
Other operating expenses - - - 0.14M -1.41200M
Interest expense 19.82M 17.44M 15.16M 10.62M 8.01M
Tax provision 26.07M 23.30M 13.40M 17.70M 15.44M
Interest income 4.07M 4.41M 5.32M 4.06M 1.42M
Net interest income -24.79600M -21.26100M -17.65500M -12.48700M -11.27900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 17.70M 15.44M
Total revenue 952.17M 871.96M 762.99M 683.88M 573.81M
Total operating expenses 804.72M 737.59M 650.28M 582.72M 483.89M
Cost of revenue 520.16M 476.28M 430.38M 397.72M 326.31M
Total other income expense net - - - - -
Discontinued operations - - - - -
Net income from continuing ops 91.52M 81.00M 71.04M 70.07M 61.38M
Net income applicable to common shares - - - 69.61M 61.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1243.13M 1083.52M 1006.95M 971.01M 800.42M
Intangible assets 99.67M 61.40M 48.56M 33.63M 30.67M
Earning assets - - - - -
Other current assets 23.79M 27.71M - - -0.00100M
Total liab 686.87M 578.16M 539.33M 562.38M 474.95M
Total stockholder equity 556.26M 505.36M 463.72M 402.65M 320.11M
Deferred long term liab - - - - 7.09M
Other current liab 0.00100M -0.00100M - 23.19M 18.88M
Common stock - - - 521.24M 520.78M
Capital stock 532.87M 524.53M 524.53M 521.24M 520.78M
Retained earnings 330.75M 264.87M 206.27M 150.32M 95.30M
Other liab - - - 9.11M 8.62M
Good will 471.10M 446.95M 434.36M 429.77M 380.41M
Other assets - - - 32.73M 31.35M
Cash 184.90M 115.04M 133.01M 125.34M 70.65M
Cash and equivalents - - - - -
Total current liabilities 218.98M 194.71M 175.26M 171.01M 145.06M
Current deferred revenue - - - - -
Net debt 227.44M 226.48M 192.03M 230.80M 226.74M
Short term debt - - - - -
Short long term debt 0.27M 0.00000M 0.00000M 9.46M 6.80M
Short long term debt total - - - - -
Other stockholder equity - - - -248.19100M -277.15400M
Property plant equipment - - - 143.60M 128.62M
Total current assets 462.84M 362.56M 335.90M 318.01M 233.71M
Long term investments - - - - -
Net tangible assets - - - -58.86000M -83.88100M
Short term investments 0.01M 0.89M 4.27M - -
Net receivables 95.24M 81.96M 62.05M 84.34M 72.23M
Long term debt 412.07M 341.52M 325.04M 346.67M 290.59M
Inventory 158.91M 136.96M 113.94M 108.34M 90.83M
Accounts payable 137.59M 114.28M 104.93M 97.86M 83.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 780.28M 720.96M 671.05M 653.00M 566.71M
Capital lease obligations 55.88M 44.18M 41.70M 43.24M 38.21M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -69.74300M -44.75700M -50.77100M -11.19200M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities - - - -69.26900M -31.92300M
Net borrowings 81.85M 8.47M -28.00000M 39.88M -41.64900M
Total cash from financing activities - - - 13.85M -61.64800M
Change to operating activities - - - -2.14000M -22.70100M
Net income 91.02M 80.55M 70.55M 69.61M 61.00M
Change in cash 74.44M -13.86200M 5.60M 54.69M -13.60200M
Begin period cash flow 115.04M 133.01M 125.34M 70.65M 84.25M
End period cash flow 184.90M 115.04M 133.01M 125.34M 70.65M
Total cash from operating activities 155.25M 109.89M 124.63M 109.46M 78.42M
Issuance of capital stock 8.34M 0.00000M 3.29M 0.45M 6.80M
Depreciation 43.96M 36.35M 34.52M 35.48M 23.05M
Other cashflows from investing activities - - - -0.00100M -0.00100M
Dividends paid -26.00200M -21.04600M 18.27M -14.57100M -13.02800M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -4.13600M -2.85900M -2.25700M - -
Other cashflows from financing activities - - - -11.90700M -13.76900M
Change to netincome - - - 6.51M 13.63M
Capital expenditures 30.61M 40.80M 38.47M 18.50M 20.73M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -11.54700M -34.78900M -6.30700M -2.14000M -22.70100M
Stock based compensation 1.05M 1.23M 2.43M 1.80M 3.29M
Other non cash items 28.62M 26.40M 24.19M 4.68M 10.62M
Free cash flow 124.64M 69.10M 86.16M 90.96M 57.69M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARSUF
Fagron NV		 - -% 26.53 18.17 15.43 2.04 3.00 2.17 11.41
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Fagron NV

Venecoweg 20A, Nazareth, Belgium, 9810

Key Executives

Name Title Year Born
Mr. Rafael Padilla CEO & Exec. Director 1978
Ms. Karin de Jong CFO & Exec. Director 1979
Ms. Vera Bakker Chief Operating Officer 1972
Karen Berg Global Investor Relations Mang. NA
Mr. Johan Verlinden Head of Legal, Mergers & Acquisitions NA
Mr. Ivan Jose Marostica Area Leader Latin America NA
Mr. Andrew C. Pulido Area Leader North America NA
Mr. Rafael Padilla CEO & Executive Director 1978
Ms. Karin de Jong CFO & Executive Director 1979
Karen Berg Global Investor Relations Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.